CORESTEMCHEMON Inc. Logo

CORESTEMCHEMON Inc.

Develops stem cell therapies and provides non-clinical CRO preclinical services.

166480 | KO

Overview

Corporate Details

ISIN(s):
KR7166480004
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로255번길 24 (삼평동), 성남시

Description

CORESTEMCHEMON Inc. is a biotechnology company operating through two main divisions: a biopharmaceutical unit and a non-clinical Contract Research Organization (CRO) unit. The biopharmaceutical division is dedicated to the research and development of new drugs based on stem cell therapy technology. Its clinical pipeline primarily targets neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), cerebellar ataxia, and multiple sclerosis, as well as autoimmune diseases like systemic lupus erythematosus (SLE) and fibrosis. The non-clinical CRO division provides comprehensive preclinical services, conducting essential toxicity and efficacy evaluations for pharmaceuticals, biopharmaceuticals, cosmetics, and medical devices to support regulatory approval processes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-29 00:00
자기주식처분결과보고서
Korean HTML 19.3 KB
2025-12-24 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 118.9 KB
2025-12-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.7 KB
2025-12-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.0 KB
2025-12-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.0 KB
2025-12-23 00:00
주요사항보고서(자기주식처분결정)
Korean HTML 34.8 KB
2025-09-16 00:00
유상증자1차발행가액결정 (주주배정후 실권주 일반공모)
Korean HTML 8.6 KB
2025-09-16 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean HTML 38.9 KB
2025-09-16 00:00
[발행조건확정]증권신고서(지분증권)
Korean HTML 291.4 KB
2025-09-16 00:00
투자설명서
Korean HTML 3.3 MB
2025-09-16 00:00
권리락 (유상증자)
Korean HTML 3.5 KB
2025-09-12 00:00
임원ㆍ주요주주특정증권등거래계획보고서
Korean HTML 44.4 KB
2025-09-08 00:00
[기재정정]증권신고서(지분증권) (2025.10)
Korean HTML 3.5 MB
2025-09-01 00:00
[기재정정]증권신고서(지분증권) (2025.10)
Korean HTML 3.8 MB
2025-08-18 00:00
주요사항보고서(유상증자결정)
Korean HTML 35.4 KB

Automate Your Workflow. Get a real-time feed of all CORESTEMCHEMON Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CORESTEMCHEMON Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CORESTEMCHEMON Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.